EFFECT OF CLOZAPINE ON D-FENFLURAMINE-EVOKED NEUROENDOCRINE RESPONSES IN SCHIZOPHRENIA AND ITS RELATIONSHIP TO CLINICAL IMPROVEMENT

被引:31
作者
CURTIS, VA
WRIGHT, P
REVELEY, A
KERWIN, R
LUCEY, JV
机构
[1] Institute of Psychiatry, London SE5 8AF, De Crespigny Park
基金
英国惠康基金;
关键词
D O I
10.1192/bjp.166.5.642
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background. Clozapine is an effective antipsychotic that has high affinity for serotonin type 2 (5-HT2) receptors. The importance of 5-HT antagonism in the overall clinical efficacy of clozapine is unclear. Using a neuroendocrine strategy we tested the hypothesis that clinical response to clozapine is related to alteration in 5-HT function. Method. Ten treatment-resistant schizophrenic subjects were treated with clozapine for a mean of 10.3 (s.e. 0.9) weeks; d-fenfluramine (DFEN) challenge tests were performed before and after treatment with concurrent clinical ratings (BPRS, SAPS, SANS) made at the time of testing. Results. All patients showed clinical improvement following treatment with clozapine. In addition, clozapine produced a significant attenuation of prolactin (PRL) and cortisol (CRT) response to DFEN challenge. Change in symptom ratings correlated significantly with reduction in PRL response to DFEN challenge. Conclusions, These data show that functional alterations occur in the 5-HT system following response to clozapine and lend support to studies suggesting that 5-HT is an important component to the spectrum of action of clozapine.
引用
收藏
页码:642 / 646
页数:5
相关论文
共 24 条
[1]  
ALTAR CA, 1986, BRAIN RES BULL, V16, P517
[2]  
American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd
[3]  
Andreasen N.C., 1981, SCALE ASSESSMENT NEG
[4]   SIMPLE COMPETITIVE PROTEIN-BINDING ASSAY FOR PLASMA CORTISOL [J].
BAUM, CK ;
TUDOR, R ;
LANDON, J .
CLINICA CHIMICA ACTA, 1974, 55 (02) :147-154
[5]  
BENNETT JP, 1979, ARCH GEN PSYCHIAT, V36, P927
[6]   BINDING OF TYPICAL AND ATYPICAL ANTIPSYCHOTICS TO 5-HT1C AND 5-HT2 SITES - CLOZAPINE POTENTLY INTERACTS WITH 5-HT1C SITES [J].
CANTON, H ;
VERRIELE, L ;
COLPAERT, FC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 191 (01) :93-96
[7]   RITANSERIN, A SELECTIVE 5-HT(2/1C) ANTAGONIST, AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - A PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL [J].
DUINKERKE, SJ ;
BOTTER, PA ;
JANSEN, AAI ;
VANDONGEN, PAM ;
VANHAAFTEN, AJ ;
BOOM, AJ ;
VANLAARHOVEN, JHM ;
BUSARD, HLSM .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 :451-455
[8]   CENTRAL DOPAMINE-RECEPTORS MEDIATING PERGOLIDE-INDUCED ELEVATION OF SERUM CORTICOSTERONE IN RATS - CHARACTERIZATION BY THE USE OF ANTAGONISTS [J].
FULLER, RW ;
SNODDY, HD .
NEUROPHARMACOLOGY, 1984, 23 (12A) :1389-1394
[9]  
GARRATTINI S, 1987, ANN NY ACAD SCI, V499, P156
[10]   RITANSERIN ATTENUATES ANORECTIC, ENDOCRINE AND THERMAL RESPONSES TO D-FENFLURAMINE IN HUMAN VOLUNTEERS [J].
GOODALL, EM ;
COWEN, PJ ;
FRANKLIN, M ;
SILVERSTONE, T .
PSYCHOPHARMACOLOGY, 1993, 112 (04) :461-466